\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesProjects, partners, priorities and procurements – In 2023 EDA reinforced its contribution to European defence
In the Agency’s annual report for 2023, they provide an overview of EDA’s milestones reached and achievements over the year. Highlights include:
🔹Denmark joining as EDA’s 27th member
🔹Deepening ties with the U.S. Department of Defence through an Administrative Arrangement
🔹Agreeing the 2023 Capability Development Priorities
🔹Stepping up in 2023 with EDA’s two-year fast-track procedure for the joint procurement of 155mm artillery rounds
🔹Transferring EDA’s long-running helicopter programme to a new centre in Portugal
🔹Achieving Initial Operational Capability for the multinational fleet of Airbus A330 tanker and transport aircraft, a project established by EDA
Overall, in 2023, the Agency managed around 94 cooperative ad-hoc projects and programmes in capability development, training, and joint procurement, as well as Research and Technology (R&T) and innovation, with a total estimated value in the range of €664 million.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
